ZLAB stock news · Zai Lab Limited
Get alerts for ZLAB
Follow Zai Lab Limited (ZLAB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ZLABZai Lab is moving forward with its skin treatment after good early trial results.
Good for ZLABZai Lab found at least 90% signal blocking through Week 12 in 48 healthy volunteers given 200 mg or more. The results favor Zai Lab; patient tests are still ahead.
Zai Lab is raising $250 million by selling shares privately.
NeutralZai Lab plans to raise about $250 million by selling ADSs to fund zoci's global development. The funding and added shares pull in opposite directions, so the outlook remains unchanged.
Zai Lab Ltd is selling 11,340,000 shares for $22.04 each to raise about $250 million.
NeutralZai Lab plans to raise about $250 million by selling new shares for drug development and general costs. The added cash helps, but the new shares leave the outlook unchanged.
Zai Lab shares its second-quarter 2026 results and full earnings call details.
Good for ZLABZai Lab's product sales rose 11% from the prior quarter, and its commercial business stayed profitable. That supports a positive reading, though broader growth is expected in 2027.